Table 3 Univariate and multivariate Cox regression analysis of PFS.

From: Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC

Variables

Univariate

Multivariate

OR

95% CI

p value

OR

95% CI

p value

Age (years)

  

0.846

   

> 73 (median)

1.048

0.651–1.687

    

≤ 73

1

     

Sex

  

0.410

   

Male

0.818

0.506–1.320

    

Female

1

     

Treatment

  

0.816

   

RT

0.945

0.587–1.522

    

CRT

1

     

Differentiation

  

< 0.0001

  

0.008

Differentiated

0.336

0.207–0.545

 

0.493

0.292–0.831

 

Undifferentiated

1

  

1

  

Tumor length (cm)

  

0.322

   

> 5 (median)

1.280

0.786–2.084

    

≤ 5

1

     

Tumor location

Cervical

0.253

0.060–1.066

0.061

   

Upper thoracic

1.032

0.575–1.852

0.917

   

Middle thoracic

0.699

0.390–1.253

0.229

   

Lower thoracic

1

     

SDRLN (cm)

  

< 0.0001

  

< 0.0001

> 0.4 (median)

4.944

2.962–8.253

 

3.076

1.718–5.507

 

≤ 0.4

1

  

1

  

TNM stage

  

< 0.0001

  

0.005

I–II

0.189

0.114–0.313

 

0.421

0.230–0.770

 

III–IV

1

  

1

  

Adverse events (> Grade 2)

  

0.095

   

Yes

1.589

0.923–2.737

    

No

1

     

Before radiotherapy

VEGF (high/low group)

2.436

1.411–4.207

0.001

1.819

1.040–3.182

0.036

GPS (high/low group)

1.616

1.006–2.595

0.047

1.218

0.613–2.418

0.547

CAR (high/low group)

1.765

1.060–2.937

0.029

1.173

0.560–2.454

0.672

CLR (high/low group)

1.400

0.847–2.312

0.189

   

During radiotherapy

VEGF (high/low group)

1.793

1.089–2.951

0.022

1.531

0.907–2.584

0.111

GPS (high/low group)

1.725

1.037–2.868

0.036

0.675

0.320–1.422

0.301

CAR (high/low group)

1.952

1.215–3.139

0.006

1.574

0.822–3.015

0.171

CLR (high/low group)

1.611

0.844–3.073

0.148

   

End of radiotherapy

VEGF (high/low group)

4.820

2.934–7.919

< 0.0001

2.174

1.620–4.803

< 0.0001

GPS (high/low group)

1.956

1.101–3.474

0.022

0.501

0.866–2.794

0.140

CAR (high/low group)

1.481

0.914–2.399

0.110

   

CLR (high/low group)

2.221

1.358–3.633

0.001

0.423

0.802–2.256

0.261

1 m after radiotherapy

VEGF (high/low group)

7.539

4.215–13.48

< 0.0001

4.934

2.600–9.365

< 0.0001

GPS (high/low group)

2.094

1.281–3.423

0.003

1.155

0.563–2.369

0.695

CAR (high/low group)

2.045

1.268–3.298

0.003

1.187

0.612–2.301

0.612

CLR (high/low group)

1.278

0.633–2.582

0.494

   

3 m after radiotherapy

VEGF (high/low group)

5.786

3.280–10.20

< 0.0001

4.095

2.265–7.403

< 0.0001

GPS (high/low group)

3.924

2.384–6.461

< 0.0001

2.404

1.394–4.146

0.002

CAR (high/low group)

2.951

1.821–4.780

< 0.0001

0.706

0.358–1.391

0.314

CLR (high/low group)

3.781

2.277–6.276

< 0.0001

1.628

0.757–3.502

0.212

  1. RT radiotherapy, CRT chemoradiotherapy, SDRLN short diameter of residual lymph node, VEGF vascular endothelial growth factor, GPS Glasgow prognostic score, CAR C reactive protein/albumin ratio, CLR C reactive protein/lymphocyte ratio, OR odd ratio, CI confidence interval.
  2. The bold entries represent statistically significant.
Back to article page